Colombia: The Top Choice for Medtech Early-Feasibility and First-in-Human Trials

Discover why Colombia is ideal for Medtech early-feasibility studies (EFS) and first-in-human (FIH) clinical trials. As the third-largest country in Latin America and an Organization for Economic Cooperation and Development (OECD) member, Colombia offers strategic advantages with its free trade agreements with the US and the EU and its prime geographical location in the same Eastern Standard Time (EST) zone. These factors have made Colombia the top destination in Latin America for first-in-human Medtech clinical trials.

After a fast institutional review board (IRBs are also called ethics committees or ECs) approval, the Ministry of Health in Colombia ensures a predictable study review process, typically taking between 90 and 120 days. Additionally, sponsors can expect significant cost savings, with hospital fees reduced by about 30-50%.

Explore our infographic to see why prominent Medtech sponsors like DirectFlow, InterVene, Mitralign, MitraSpan, Kona Medical, Avinger, CeloNova, Libella, enVVeno, ReGelTec, Sonnest, PAVmed, Watershed, Spine Stabilization Technologies, and many others choose Colombia for their clinical research needs. Discover the unparalleled benefits that make Colombia the prime destination for your Medtech clinical trial.